Search this site
Skip to main content
Skip to navigation
MS-Selfie
Home
COVID-19 & MS
Case Studies
Case study 1
Case study 2
Case study 3
Case study 4
Case study 5
Case study 6
Ask a COVID-19 question?
COVID-19 Questions
Q: COVID19 infection
Q: Severe COVID-19 infection
Q: Avoiding hospital appointments
Q: What if I have a relapse?
Q: Can I postpone or stop my natalizumab infusions?
Q: Should I suspend blood monitoring during the COVID-19 pandemic?
Q: Are there any people with MS who have had COVID-19 infection?
Q: Does COVID-19 cause MS to relapse?
Q: Should I self-isolate because I have MS?
Q: Should I stop my DMT if I become infected with COVID-19?
Q: Will my immune system be able to fight COVID-19 if I become infected?
Q: What is a safe lymphocyte count?
Q: Reliable sources of information on COVID-19?
Q: Am I at increased risk of COVID-19 because I am on a specific DMT?
Q: How does the UK's Government Guidelines impact on me?
Q: What should I do if I get symptoms suggestive of COVID-19?
Q: What is a normal lymphocyte count?
Q: If I get severe COVID-19 will I be managed in a critical care unit?
Q: Is it safe to suspend or extend natalizumab infusions?
Q: Can relapses be assessed and managed remotely?
Q: Is there anything I can do to prepare for having COVID-19?
Q: What about COVID-19 and pregnancy?
Q: How will my DMT affect my response to a SARS-CoV-2 vaccine?
Q: How safe is cladribine to use during the COVID-19 pandemic?
Q: What can I do to prevent getting COVID-19 in my own home?
What is MS?
Do you have MS?
Type of MS
Prognostic group
Risks of no treatment
Active MS
Eligibility
Maintenance vs. IRTs
Immunosuppression
Treat-2-Target
Holistic Management
Advanced Directives
BrainHealth
Comorbidities
Diagnosis
Disease-modifying therapies
MS disease stage
Physical therapies
Prevention
Symptomatic therapies
Symptoms
Wellness
Vaccinations
Influenza vaccine
Pneumococcal vaccine
Varicella and herpes zoster vaccines
HPV
Q&A
DMTs
Interferon-beta
Switching-2-IFN-beta
Glatiramer acetate
Switching-2-GA
Mitoxantrone
Switching-2-Mitox
Natalizumab
Extended interval dosing
PML
Switching-2-Natalizumab
Fingolimod
Switching-2-fingolimod
Reducing Fingolimod Dose
Dimethyl Fumarate
Switching-2-DMF
240mg-to-120mg
Alemtuzumab
Switching-2-Alemtuzumab
Teriflunomide
14mg-to-7mg
Accelerated elimination
Switching-2-teriflunomide
Cladribine
Ocrelizumab
HSCT
Switching-2-HSCT
Stopping DMTs
Case studies
About the author
Glossary
MS-Selfie
disease-Modifying therapies
Report abuse
Page details
Page updated
Report abuse